Year
2023
-
GSK’s Jemperli Gets Regular Approval for Endometrial Cancer
-
Frequency Therapeutics Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss
-
EMA to Review Pseudoephedrine Drugs
-
FDA Places Partial Clinical Hold on Blueprint Medicines Trial
-
Soligenix Gets Refusal to File Letter for HyBryte in Cutaneous T-Cell Lymphoma
-
Labeling Changes for Aduhelm Detail Risks of ARIA Brain Bleeds
-
Kinnate Biopharma Gets Fast Track Status for Bile Duct Cancer Candidate
-
Biocon and Viatris Draw Complete Response Letter for Bevacizumab BLA
-
Maze Therapeutics to Present Phase 1 Results from First-in-Human Trial Evaluating MZE001 as a Potential Oral Treatment for Pompe Disease
-
Travere Therapeutics Announces FDA Accelerated Approval of FILSPARIᵀᴹ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy